Geographic Atrophy
Conditions
Keywords
Macular Degeneration
Brief summary
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Interventions
DRUGJNJ-81201887
JNJ-81201887 will be administered as intravitreal injection.
DRUGPrednisone
Prednisone will be administered as oral capsule.
OTHERPlacebo
Prednisone matching placebo will be administered as oral capsule.
DRUGTriamcinolone
Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
OTHERSham Procedure
Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
Sponsors
Janssen Research & Development, LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have non-subfoveal (defined as not involving the center point of the fovea) geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an area that can be measured and measures 2.5 millimeter square (mm\^2) to 17.5 mm\^2 (1- and 7- disc areas respectively), determined by the central reading center (CRC) from screening images of fundus autofluorescence (FAF) and spectral domain optical coherence tomography (SD-OCT) * If GA is multifocal, at least one focal lesion must be greater than or equal to (\>=) 1.25 mm\^2 (0.5- disc area), as assessed by the CRC * GA can be photographed in its entirety by FAF, using a 30- degree image centered on the fovea, as assessed by the CRC * Fellow eye must be present with a best corrected distance visual acuity (BCVA) of counting fingers or better * Man or woman (according to their reproductive organs and functions assigned by chromosomal complement)
Exclusion criteria
* History of transpupillary thermotherapy, photodynamic therapy or external-beam radiation therapy in the region of study eye * Any prior thermal laser in the macular region, regardless of indication * History of retinal detachment (with or without repair) * Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis * Any sign of diabetic retinopathy or central serous chorioretinopathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Global: Change From Baseline in Square Root of Geographic Atrophy (GA) Lesion Area in the Study Eye at Month 18 | Baseline and Month 18 | Change from baseline in GA lesion area in the study at month 18 eye will be measured via retinal imaging using fundus auto fluorescence (FAF). |
| United States (U.S.) Specific: Rate of Change in Untransformed GA Lesion Area in the Study Eye | Baseline to Month 18 | Rate of Change in untransformed GA lesion area in the study eye will be measured via retinal imaging using FAF. A piecewise linear mixed effects (PLME) model will be used for the primary efficacy analysis for rate of change in GA area (GAA) in the study eye. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Low Luminance Visual Acuity (LLVA) at Month 18 | Baseline and Month 18 | Best corrected LLVA will be assessed using the early treatment diabetic retinopathy study (ETDRS) chart at a starting distance of 4 meter. |
| Change From Baseline in Reading Speed at Month 18 | Baseline and Month 18 | Change from baseline in reading speed (normal luminance) as assessed by Radner reading charts will be performed in the study eye and binocularly for participants who are fluent in the languages available for the Radner Chart will be reported. |
| Change From Baseline in Retinal Sensitivity by Mesopic Microperimetry (MAIA) at Month 18 | Baseline and Month 18 | Change from baseline retinal sensitivity by MAIA will be reported. |
| Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 18 | Baseline and Month 18 | Change from baseline in BCVA will be reported and this will be measured using the ETDRS chart at a starting distance of 4 meter. |
| Change From Baseline in Functional Reading Independence (FRI) Index at Month 18 | Baseline and Month 18 | The FRI is an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD participants. Item scores reflect decreasing levels of functional reading independence. The FRI Index yields continuous mean scores (range 1 to 4), and ordinal-level scores from Level 1 = "Unable to do" to Level 4 = "Totally independent." For each FRI Index reading activity performed in the past 7 days, participants are asked about the extent to which they required vision aids, adjustments in the activity, or help from another person. |
| Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Month 18 | Baseline and Month 18 | The 2000 version of the NEI-VFQ-25, which must be interviewer-administered, includes 25 items and is scored to produce 11 subscales and a general health item. The 11 subscales include General Vision (1 item), Ocular Pain (2 items), Near Activities (3 items), Distance Activities (3 items), Social Functioning (2 items), Mental Health (2 items), Role Difficulties (2 items), Dependency (3 items), Driving (3 items), Color Vision (1 item), and Peripheral Vision (1 item). Response to each question converted to 0-100 score. Each subscale, total score equal to (=) average of items contributing to score. For each subscale and total score, score range: 0 to 100, higher score equal to less symptoms/better visual functioning. |
Countries
Australia, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom, United States
Contacts
STUDY_DIRECTORJanssen Research & Development, LLC Clinical Trial
Janssen Research & Development, LLC
Outcome results
None listed